Hemostemix Partners with CytoImmune, Boosts ACP-01 Production

Hemostemix (TSE:HEM) has released an update.

Hemostemix Inc. has entered into a definitive Manufacturing Services Agreement with CytoImmune Therapeutics, marking the restart of production for its cardiovascular stem cell therapy, ACP-01, with initial sales expected to make the company self-funding. The agreement, involving a share issuance to CytoImmune, will also cover the production costs for the first batch of commercial treatments, targeting sales of $1.1 million. This strategic partnership aims to deliver life-changing treatments for patients with severe cardiovascular diseases while ensuring significant cash flow for Hemostemix shareholders.

For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.